Hjem › Nyrekreft (nyrecellekarcinom) › Tennessee › Nashville
Kliniske studier for Nyrekreft (nyrecellekarcinom) i Nashville, TN
23 studier for Nyrekreft (nyrecellekarcinom) søker deltakere på steder i og rundt Nashville (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
RekruttererFase 1
- Research Site, Nashville
- Research Site, Nashville
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
RekruttererFase 1
- Tennessee Oncology, Nashville
A Phase 1 Study of the Safety and Tolerability of CTX-10726
RekruttererFase 1
- SCRI Oncology Partners, Nashville
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
RekruttererFase 1/2
- Vanderbilt University Medical Center ( Site 5004), Nashville
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
RekruttererFase 1
- Sarah Cannon Research Institute (SCRI), Nashville
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RekruttererFase 1
- Exelixis Clinical Site #3, Nashville
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RekruttererFase 2
- Vanderbilt University/Ingram Cancer Center, Nashville
DESTINY-PANTUMOUR04
RekruttererObservasjonsstudie
- Research Site, Nashville
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RekruttererObservasjonsstudie
- Vanderbilt University Medical Center, Nashville
Casdatifan for the Treatment of Refractory Metastatic Clear Cell Renal Cell Carcinoma
RekruttererFase 1
- Vanderbilt University Medical Center, Nashville
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
RekruttererFase 1/2
- Vanderbilt University Medical Center, Nashville
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
RekruttererFase 1/2
- Sarah Cannon Research Institute, Nashville
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RekruttererFase 1/2
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, PLLC- Elliston Place Plaza, Nashville
- og 11 flere
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RekruttererFase 1
- Scri Oncology Partners, Nashville
- Vanderbilt Medical Center, Nashville
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
RekruttererFase 2
- Vanderbilt-Ingram Cancer Center, Nashville
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
RekruttererFase 3
- Vanderbilt University/Ingram Cancer Center, Nashville
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
RekruttererFase 2
- Vanderbilt University/Ingram Cancer Center, Nashville
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
RekruttererFase 1
- Vanderbilt- Ingram Cancer Center, Nashville
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
RekruttererFase 1/2
- Vanderbilt University Medical Center, Nashville
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
RekruttererFase 1
- SCRI Oncology Partners, Nashville
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
RekruttererFase 1
- Xencor Investigative Site, Nashville
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
RekruttererFase 1
- SCRI - Oncology Partners, Nashville
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
Rekrutterer
- Vanderbilt-Ingram Cancer Center, Nashville
Nyrekreft (nyrecellekarcinom)-studier i andre byer
- Houston, TX35 studier
- New York City, NY27 studier
- Dallas, TX23 studier
- St. Louis, MO23 studier
- Los Angeles, CA20 studier
- Boston, MA16 studier
- Baldwin Park, CA16 studier
- Philadelphia, PA15 studier
- Pittsburgh, PA15 studier
- Queens, NY15 studier
- Rochester, MN14 studier
- Cleveland, OH14 studier
Andre studier i Nashville
- Ikke-småcellet lungekreft97 studier
- Brystkreft81 studier
- Metastatisk kreft70 studier
- Kolorektal kreft69 studier
- Kreft (alle typer)65 studier
- Eggstokkreft49 studier
- Prostatakreft43 studier
- Lungekreft40 studier
- Plateepitelcancer i hode og hals39 studier
- Pankreaskreft39 studier
- Endometriekreft38 studier
- Melanom33 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.